Drug intelligence / Profile preview

varenicline + naltrexone

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination pharmacotherapy that targets both nicotine and alcohol dependence simultaneously. Varenicline is a partial agonist at nicotinic acetylcholine receptors (primarily α4β2) that helps reduce smoking by decreasing craving and blocking reinforcement from smoking. Naltrexone is an opioid receptor antagonist that blocks the euphoric effects associated with alcohol consumption, potentially reducing drinking behavior. This combination has been studied for treating individuals who both smoke cigarettes and drink alcohol heavily.

Other names: naltrexone and varenicline combination

Targets

DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)CHRNA7 (α7 nicotinic receptor)

Beyond the preview

Go deeper on varenicline + naltrexone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on varenicline + naltrexone.

Explore the full profile